|Articles|March 21, 2022
Daily Medication Pearl: Montelukast Sodium (Singulair)
Author(s)Saro Arakelians, PharmD
Singulair is a leukotriene receptor antagonist indicated for prophylaxis and chronic treatment of asthma.
Advertisement
Medication Pearl of the Day: Montelukast Sodium (Singulair)
Indication: Singulair is a leukotriene receptor antagonist indicated for prophylaxis and chronic treatment of asthma in patients 12 months of age and older.
Insight:
- Dosing: Once daily in the evening for patients 12 months of age and older.
- Dosage forms: Singulair 10 mg film-coated tablets, 5 mg and 4 mg chewable tablets, 4 mg oral granules.
- Adverse events: Most common adverse reactions (incidence ≥5% and greater than placebo listed in descending order of frequency) are upper respiratory infection, fever, headache, pharyngitis, cough, abdominal pain, diarrhea, otitis media, influenza, rhinorrhea, sinusitis, and otitis.
- Mechanism of action: In asthma, leukotriene-mediated effects include airway edema, smooth muscle contraction, and altered cellular activity associated with the inflammatory process. In allergic rhinitis, cysteinyl leukotrienesare released from the nasal mucosa after allergen exposure during both early and late-phase reactions and are associated with symptoms of allergic rhinitis.
- Manufacturer: Merck
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- IMS 2025: Improving Outcomes with Bispecifics in Multiple Myeloma
September 19th 2025
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
Effectively Managing Immunizations in the Long-Term Care Setting
2
Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety
3
NCCN Guideline Update in SCLC Adds Maintenance Lurbinectedin, Removes Chemotherapy-Free Interval
4
New Teclistamab Study in Multiple Myeloma Shows Improved Tolerance, Responses
5